Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease

Abstract

Background: Currently a definitive diagnosis for Alzheimer’s disease (AD) is not readily available to the wider community as the gold standard markers of AD are either invasive and/or expensive. Therefore, there is an urgent need for a relatively low‐cost blood test that can be readily used in clinical settings.